Cobicistat as a Pharmacoenhancer in Pregnancy and Postpartum: Progress to Date and Next Steps.
作者信息
Eke Ahizechukwu C, Mirochnick Mark H
机构信息
Division of Maternal Fetal Medicine & Clinical Pharmacology, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Doctoral Training Program (PhD), Graduate Training Program in Clinical Investigation (GTPCI), Johns Hopkins University School of Public Health, Baltimore, MD, USA.
出版信息
J Clin Pharmacol. 2019 Jun;59(6):779-783. doi: 10.1002/jcph.1397. Epub 2019 Mar 1.
Abstract
摘要
相似文献
1
Cobicistat as a Pharmacoenhancer in Pregnancy and Postpartum: Progress to Date and Next Steps.
J Clin Pharmacol. 2019 Jun;59(6):779-783. doi: 10.1002/jcph.1397. Epub 2019 Mar 1.
2
Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy.
J Clin Pharmacol. 2020 Dec;60(12):1537-1550. doi: 10.1002/jcph.1714. Epub 2020 Aug 14.
3
Ritonavir and cobicistat as pharmacokinetic enhancers in pregnant women.
Expert Opin Drug Metab Toxicol. 2019 Jul;15(7):523-525. doi: 10.1080/17425255.2019.1628947. Epub 2019 Jun 11.
4
Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.
AIDS Rev. 2016 Apr-Jun;18(2):101-11.
5
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
J Antimicrob Chemother. 2017 Oct 1;72(10):2857-2861. doi: 10.1093/jac/dkx246.
6
Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
J Antimicrob Chemother. 2017 Sep 1;72(9):2574-2577. doi: 10.1093/jac/dkx165.
7
Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV.
Expert Opin Drug Metab Toxicol. 2019 Nov;15(11):927-935. doi: 10.1080/17425255.2019.1685495. Epub 2019 Nov 3.
8
Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.02275-17. Print 2018 Feb.
9
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
J Infect Dis. 2013 Jul;208(1):32-9. doi: 10.1093/infdis/jit122. Epub 2013 Mar 26.
10
Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: A case for apixaban.
Int J STD AIDS. 2019 Jun;30(7):718-722. doi: 10.1177/0956462419832099. Epub 2019 Apr 11.
引用本文的文献
1
A systematic review of pregnancy-related clinical intervention of drug regimens due to pharmacokinetic reasons.
Front Med (Lausanne). 2023 Nov 29;10:1241456. doi: 10.3389/fmed.2023.1241456. eCollection 2023.
2
Physiologic Changes During Pregnancy and Impact on Small-Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response.
J Clin Pharmacol. 2023 Jun;63 Suppl 1(Suppl 1):S34-S50. doi: 10.1002/jcph.2227.
3
Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV).
Expert Rev Anti Infect Ther. 2022 Nov;20(11):1413-1424. doi: 10.1080/14787210.2022.2125868. Epub 2022 Sep 20.
4
Prediction and prevention of preterm birth in pregnant women living with HIV on antiretroviral therapy.
Expert Rev Anti Infect Ther. 2022 Jun;20(6):837-848. doi: 10.1080/14787210.2022.2046463. Epub 2022 Mar 1.
5
An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics.
J Basic Clin Physiol Pharmacol. 2021 Dec 8;33(5):581-598. doi: 10.1515/jbcpp-2021-0312. eCollection 2022 Sep 1.
6
Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement.
Clin Pharmacol Ther. 2021 Jul;110(1):36-48. doi: 10.1002/cpt.2048. Epub 2020 Oct 15.
7
Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy.
J Clin Pharmacol. 2020 Dec;60(12):1537-1550. doi: 10.1002/jcph.1714. Epub 2020 Aug 14.
8
Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV.
Clin Pharmacokinet. 2020 Oct;59(10):1185-1194. doi: 10.1007/s40262-020-00915-w.
9
Tenofovir alafenamide use in pregnant and lactating women living with HIV.
Expert Opin Drug Metab Toxicol. 2020 Apr;16(4):333-342. doi: 10.1080/17425255.2020.1738384. Epub 2020 Mar 17.
10
Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02260-19.
本文引用的文献
1
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.
Lancet HIV. 2018 Dec 13. doi: 10.1016/S2352-3018(18)30296-0.
2
Increasing the Participation of Pregnant Women in Clinical Trials.
JAMA. 2018 Nov 27;320(20):2077-2078. doi: 10.1001/jama.2018.17716.
3
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
Ann Pharmacother. 2017 Nov;51(11):1008-1022. doi: 10.1177/1060028017717018. Epub 2017 Jun 19.
4
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.
AIDS Res Ther. 2014 Dec 1;11:39. doi: 10.1186/1742-6405-11-39. eCollection 2014.
5
Designing drug trials: considerations for pregnant women.
Clin Infect Dis. 2014 Dec 15;59 Suppl 7(Suppl 7):S437-44. doi: 10.1093/cid/ciu709.
6
Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19772. doi: 10.7448/IAS.17.4.19772. eCollection 2014.
7
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
J Infect Dis. 2013 Jul;208(1):32-9. doi: 10.1093/infdis/jit122. Epub 2013 Mar 26.
8
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Lancet. 2012 Jun 30;379(9835):2439-2448. doi: 10.1016/S0140-6736(12)60917-9.
9
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
Lancet. 2012 Jun 30;379(9835):2429-2438. doi: 10.1016/S0140-6736(12)60918-0.
10
A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.
Br J Clin Pharmacol. 2012 Nov;74(5):873-85. doi: 10.1111/j.1365-2125.2012.04363.x.
Zotero 插件